Objectives: To assess AIDAI score and evaluate correlation between AIDAI and disease/response characteristics over 16 weeks (wks) of CAN treatment in CLUSTER. Methods: CLUSTER study design and results have been presented.
Inclusion criteria: i) diagnosis of JIA: ii)age ≤2 years old, iii)planned start of biological therapy due to JIA; iv)negative screening for tuberculosis; v)provided informed consent. Patients have undergone standard clinical assessment every 3 months. Disease activity is measured using JADAS27 in all age groups. ANA, HLAB27, RF and anti-CCP detection are highly recommended. Uveitis and other comorbid conditions should also be fixed. Results: 339 patients were enrolled into the study during 3 years. 64% of patients are girls. Mean age-10.98±4.41 years, with mean disease duration -5.81±3.48 years. The duration of the period between diagnosis and biologics start was 54.31±40.28 months. Comorbid conditions were found in 41.03% patients. In 14.65% of the patients uveitis was diagnosed. Most common JIA subtypes in patients receiving biologics are pJIA with negative RF (45%), sJIA (20%), enthesitis-associated JIA (11%) and persistent oligoarthritis (11%). 67.3% of enrolled patients received adalimumab (ADA); 27.9%>tocilizumab (TOZ) and 4.8%>etanercept, respectively. During observational period biologics was discontinued in 19.8% of patients due to different reasons: adverse events were observed in 6.7% (ADA) and 16.7% (TOZ), insufficient efficiency of 23.3% (ADA) and 33.3% (TOZ), remission -6.7% (ADA); drug absence -63.3% (ADA) and 50% (TOZ), respectively. Comparative analysis of ADA and TOZ efficacy was performed in the 144 patients with pJIA with negative RF. Administration either ADA or TOZ resulted in statistically significant reducing of disease activity according to JADAS27. In ADA group after 3 months of administration JADAS27 decreased from 16.3±10.3 to 10.0±7.8 (p<0.00001). In TOZ group after 3 months of administration JADAS27 reduced from 22.2±12.2 to 13.1±9.1 (p=0.0012). The functional disability of the patients also statistically significant decrease in both treatment group starting from 3 months of administration: 1.1±0.8 to 0.7±0.7 (p=0.0081) in ADA and 1.6±1.0 to 1.0±0.7 in TOZ, respectively. Conclusions: Ukrainian national registry of JIA patients provides real-life longterm data concerning safety, efficacy, outcomes and comparative analysis of biologics in Ukrainian population of JIA patients. Data collection continues and the data received expected to be a background for clinical decision-making in future. Background: Juvenile localised scleroderma (jlSc) is an orphan disease. Most patient respond to treatment ot methotrexate or mycophenolate. In case of nonresponse or partial response, based on the promising tocilizumab (TOC) data of adult systemic sclerosis studies, TOC seems to be a promising option. There is no publication regarding the effectiveness of tocilizumab in jLS. Objectives: To assess the effectivity of TOC in jlSC patients, who had nonresponse or partial response on conventional therapy. Methods: Participants of the pediatric rheumatology email board were asked, if they follow patients with jlSc, who are treated with TOC. Clinical characteristics and the response to TOC was assessed. Results: Six centers responded to the survey from the email board, with around 800 participatns, and reported 11 patients. The mean age of the patients at disease onset was 5.5 years. Disease duration at time of the intiation of TOC was 53.5. months (range 9 to 109). 5 patients had linear subtype, 3 of them with facial involvement, 2 of them Parry Romberg and one of them coup de sabre. Three had generalized subtype, 2 mixed subtype and 1 limited subtype/morphea. Before starting TOC patients received 10/11 Methotrexate, 7/11 Mycophenolate, 1 abatacept and 1 anti-TNF therapy. Reason to start TOC was in 9 patients increase in Localised Scleroderma Activity Index [1] (mLoSSI). In two patients increased extracutaneous activity was the indication, in one increased activity of arthritis and in the other increased activity of the central nervous system involvement.
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